Phase II evaluation of maytansine in refractory non-Hodgkin's lymphoma: a Southwest Oncology Group study. 1982

V Ratanatharathorn, and N Gad-el-Mawla, and H E Wilson, and J D Bonnet, and S E Rivkin, and R Mass

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008223 Lymphoma A general term for various neoplastic diseases of the lymphoid tissue. Germinoblastoma,Lymphoma, Malignant,Reticulolymphosarcoma,Sarcoma, Germinoblastic,Germinoblastic Sarcoma,Germinoblastic Sarcomas,Germinoblastomas,Lymphomas,Lymphomas, Malignant,Malignant Lymphoma,Malignant Lymphomas,Reticulolymphosarcomas,Sarcomas, Germinoblastic
D008453 Maytansine An ansa macrolide isolated from the MAYTENUS genus of East African shrubs. Maitansine,DMMO-Maytansine,Emtansine,Maytansinoid DM1,Maytansinoid DM4,Mertansine,N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine,Ravtansine,Soravtansine,DM1, Maytansinoid,DM4, Maytansinoid,DMMO Maytansine
D010078 Oxazines Six-membered heterocycles containing an oxygen and a nitrogen.
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

V Ratanatharathorn, and N Gad-el-Mawla, and H E Wilson, and J D Bonnet, and S E Rivkin, and R Mass
October 2000, Anti-cancer drugs,
V Ratanatharathorn, and N Gad-el-Mawla, and H E Wilson, and J D Bonnet, and S E Rivkin, and R Mass
December 1977, Cancer treatment reports,
V Ratanatharathorn, and N Gad-el-Mawla, and H E Wilson, and J D Bonnet, and S E Rivkin, and R Mass
March 1986, Seminars in oncology,
V Ratanatharathorn, and N Gad-el-Mawla, and H E Wilson, and J D Bonnet, and S E Rivkin, and R Mass
November 1991, Investigational new drugs,
V Ratanatharathorn, and N Gad-el-Mawla, and H E Wilson, and J D Bonnet, and S E Rivkin, and R Mass
August 1986, Cancer treatment reports,
V Ratanatharathorn, and N Gad-el-Mawla, and H E Wilson, and J D Bonnet, and S E Rivkin, and R Mass
January 1987, Investigational new drugs,
V Ratanatharathorn, and N Gad-el-Mawla, and H E Wilson, and J D Bonnet, and S E Rivkin, and R Mass
July 1976, Cancer,
V Ratanatharathorn, and N Gad-el-Mawla, and H E Wilson, and J D Bonnet, and S E Rivkin, and R Mass
January 1993, Journal of neuro-oncology,
V Ratanatharathorn, and N Gad-el-Mawla, and H E Wilson, and J D Bonnet, and S E Rivkin, and R Mass
January 1999, Investigational new drugs,
V Ratanatharathorn, and N Gad-el-Mawla, and H E Wilson, and J D Bonnet, and S E Rivkin, and R Mass
January 1980, Cancer treatment reports,
Copied contents to your clipboard!